No Data
Reported Earlier, Cellectar Highlights Path Toward Accelerated Approval For Iopofosine I 131 and Expands Radioconjugate Development
Cellectar Biosciences Reports 83.6% Overall Response Rate for Iopofosine I 131 in Phase 2 CLOVER-WaM Study, Plans for Advancement and Regulatory Approvals
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase During the JP Morgan Healthcare Conference
Express News | Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase During the JP Morgan Healthcare Conference
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $1
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Cuts Target Price to $1
C00ker : Possible ?![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Teo knows OP C00ker : no looks weak